Presently, natural and synthetic compounds activating NRF2 or inhibiting downstream proteins and pathways are being explored in the treatment of psoriasis, multiple sclerosis, pancreatic cancer, and possibly others. Here, NFE2L2 is linked to familial pancreatic carcinoma.